MIRM News

Nine companies entered the public market this week, led by customer experience software provider Medallia (MDLA) with a first day pop of 76%. The software company priced at $21, well above the range, to raise $326 million at a fully diluted valuation of $3.6 billion. Medallia’s growth accelerated to 32% in the most recent quarter, and it boasts 32...read more

Mirum Pharmaceuticals, a late-stage biotech developing therapies for rare cholestatic liver diseases, raised $75 million by offering 5.0 million shares at $15, the midpoint of the $14 to $16 range. Insiders had indicated on purchasing $35 million of the IPO (47% of the deal). Mirum Pharmaceuticals plans to list on the Nasdaq under the symbol MIRM. Citi, Evercore ISI and...read more

July's post-holiday flood of IPOs is upon us, with nine diverse offerings and a direct listing scheduled for the second-most active week of the year. The three largest IPOs come from Asia, Europe, and South America, but based on the strong reception of recent tech unicorns, Medallia (MDLA) may get the most eyeballs. DouYu (DOYU) is set to...read more

Mirum Pharmaceuticals, a Phase 2 biotech developing therapies for rare liver diseases, announced terms for its IPO on Monday. The Foster City, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Mirum Pharmaceuticals would command a fully diluted market value of $377 million. Mirum...read more